SILVERCREST ASSET MANAGEMENT GROUP LLC
Position in NUVB — Nuvation Bio Inc.
CIK 1232395
NEW YORK, NY
Position in NUVB
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$3,107,603
New position
Shares Held
724,383
first reported quarter
Ownership
0.208%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 63%
Shared 0%
None 37%
Position in Biotechnology
Healthcare · as of Mar 31, 2026SILVERCREST ASSET MANAGEMENT GROUP LLC holds $95,938,613 across 21 Biotechnology names. NUVB ranks #11 (3.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VCEL |
Vericel Corp
|
959,207 | $30,857,689 | |
| 2 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
15,963 | $8,356,151 | |
| 3 | MIRM |
Mirum Pharmaceuticals, Inc.
|
80,991 | $7,481,948 | |
| 4 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
16,358 | $7,304,501 | |
| 5 | ARWR |
Arrowhead Pharmaceuticals, Inc.
|
108,413 | $6,797,495 | |
| 6 | CRNX |
Crinetics Pharmaceuticals, Inc.
|
163,633 | $5,943,150 | |
| 7 | PTGX |
Protagonist Therapeutics, Inc
|
47,931 | $5,051,927 | |
| 8 | ZYME |
Zymeworks Inc.
|
163,649 | $4,097,770 |
All Filings in NUVB
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $3,107,603 | 724,383 | Shares | Sole | 2026-05-15 | |
| No filing history on record for this holder in this stock. | ||||||